PR: Heidelberg Pharma Announces Changes to the Executive Management Board – Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer

Ladenburg, Germany, 24 November 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the Supervisory Board has revoked the appointment of Professor Andreas Pahl as member of the Executive Management Board and Chief Executive Officer, and has instead appointed Dr Dongzhou Jeffery Liu as Chairman of the Executive Management Board and new Chief Executive Officer, with immediate effect.

Today, Dr Liu has stepped down from his position as a member of the Supervisory Board of Heidelberg Pharma, with effect as of 23 December 2025. His permanent appointment as Chairman of the Executive Management Board and Chief Executive Officer will become effective as of 24 December 2025. For the transition period from today until 23 December 2025 he will be seconded as a deputy member to the Executive Management Board pursuant to section 105 (2) of the German Stock Corporation Act (Aktiengesetz).

Dr. Karl Benedikt Biesinger, Chairman of the Supervisory Board of Heidelberg Pharma AG, commented: "On behalf of the Supervisory Board, I would like to thank Professor Pahl for his many years of service on the Executive Management Board of Heidelberg Pharma. With his scientific expertise, he shaped our unique Amanitin-based ADC technology to the lead clinical stage ADC project HDP-101. We heartly welcome Dr Liu as new Chief Executive Officer of the Company, we are convinced that he will further strengthen Heidelberg Pharma’s profile with great dedication.”

Dr Liu is Chief Scientific Officer (CSO) and President of Huadong Global Development at Huadong Medicine in Hangzhou, China. Prior to that he held various leading positions in the pharma industry in the US, including GlaxoSmithKline, Wyeth (now Pfizer) and Forest Labs (now Abbvie). His more than 25 years of industry experience include clinical and preclinical research & development of medicinal products, including ADC products.

Dr Jeffery Liu, Chief Executive Officer of Heidelberg Pharma, added: “I am very pleased to join the company as CEO. I am confident that Heidelberg Pharma’s ATAC technology has great potential for the effective treatment of cancer patients as shown by the latest clinical data with HDP-101. I am looking forward to leading the Company on its journey towards a new generation of ADC products.”